Larkspur Biosciences Initiates First-in-Human Trial of Novel Protein Degrader LRK-4189 for Colorectal Cancer
核心洞察
Larkspur Biosciences (搜索) has dosed the first participant in a Phase 1 clinical study of LRK-4189 (搜索), a first-in-class targeted protein degrader targeting PIP4K2C (搜索) for microsatellite stable colorectal cancer (搜索) treatment.
The oral drug represents a novel therapeutic approach that destroys cancer cells by targeting cancer cell fitness mechanisms, specifically degrading the lipid kinase PIP4K2C (搜索) to trigger intrinsic cancer cell death.
The single-ascending dose trial will evaluate safety, tolerability, and pharmacokinetics in approximately 40 healthy volunteers in the UK before advancing to patient studies.
Larkspur Biosciences (搜索) has achieved a significant milestone by dosing the first participant in a Phase 1 clinical study of LRK-4189 (搜索), a first-in-class targeted protein degrader designed to treat microsatellite stable (MSS) colorectal cancer (搜索) and other solid tumors (搜索). The Cambridge, Massachusetts-based company announced that its lead candidate targets PIP4K2C (搜索), a lipid kinase that plays a crucial role in cancer cell fitness.
Novel Mechanism Targets Cancer Cell Fitness
LRK-4189 (搜索) represents a pioneering approach to cancer therapy by targeting cancer cell fitness rather than traditional oncogenic pathways. The oral drug functions as a targeted protein degrader of phosphatidylinositol 5-phosphate 4-kinase, type II, gamma (PIP4K2C (搜索)), a lipid kinase that cancer cells co-opt to increase their fitness by evading immune surveillance and adapting to stress conditions.
"Given the preclinical safety and measurable biomarkers of LRK-4189 (搜索) activity, starting in healthy volunteers is the most direct way to understand its pharmacology and define a biologically meaningful dose," said Catherine Sabatos-Peyton, Ph.D., CEO of Larkspur Biosciences (搜索). "This approach positions us to begin patient studies at dose levels that matter on day one."
The degradation of PIP4K2C (搜索) by LRK-4189 (搜索) leads to intrinsic cancer cell death, triggering multiple killing mechanisms in difficult-to-treat cancer cells. This mechanism addresses a previously elusive therapeutic target, as PIP4K2C is broadly expressed in many hard-to-treat cancers and has been associated with poor outcomes in colorectal and breast cancers.
Addressing Significant Unmet Medical Need
The clinical development of LRK-4189 (搜索) targets a substantial patient population, with MSS colorectal cancer (搜索) accounting for approximately 85% of all colorectal cancer cases. According to the American Cancer Society, approximately 150,000 cases of colorectal cancer are diagnosed annually in the United States, making this a significant area of unmet medical need.
Antoni Ribas, M.D., Ph.D., professor of medicine, surgery, and molecular medical pharmacology at UCLA and Past President of the American Association for Cancer Research, emphasized the therapeutic potential: "While it's been established that PIP4K2C (搜索) is broadly expressed in many hard-to-treat cancers, including colorectal cancer (搜索), this pathway has been elusive to engage with therapeutically until now. Larkspur's data on LRK-4189 (搜索) in preclinical models of cancer are compelling."
Phase 1 Study Design and Timeline
The Phase 1 study is structured as a single-ascending dose trial that will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of LRK-4189 (搜索) in healthy volunteers. The United Kingdom-based study expects to enroll approximately 40 participants, with clinical program management and recruitment handled by Quotient Sciences.
This healthy volunteer approach allows researchers to establish early tolerability profiles and pharmacological parameters before advancing to patient populations. Sabatos-Peyton indicated that the company looks forward to sharing study progress in the following year, suggesting potential data readouts in 2026.
Platform Technology and Scientific Foundation
Larkspur Biosciences (搜索) has built its therapeutic approach around the concept of cancer cell fitness, developing therapies that decrease cancer cell fitness and sensitize cells to both intrinsic and extrinsic mechanisms of killing. The company's proprietary bioinformatics platform, LarkX, couples machine learning with tumor genetics to discover cancer cell fitness pathways and enrich clinical strategies for potential responders across multiple cancer types.
The scientific foundation of the company includes notable founders Lewis C. Cantley, Ph.D., professor of medicine at Dana-Farber Cancer Institute and professor of cell biology at Harvard Medical School; Vijay K. Kuchroo, DVM, Ph.D., professor of neurology at Harvard Medical School and senior scientist at Brigham and Women's Hospital; and Nathanael Gray, Ph.D., professor of chemical and systems biology at Stanford University.